IP Library Patent Application 13189179
Patent Application
App. No. 13/189,179

APPARATUS AND METHODS FOR NON-INVASIVE BODY CONTOURING

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/189,179
Abstract

Methods and devices for applying high intensity focused ultrasound to modulate collagen in animal tissue (such as to disrupt collagen fibrils in a mammal, such as a human), particularly to enhance the aesthetic appearance of skin, and/or to otherwise improve skin conditions.

Claims (68)

1 . A method of non-invasively disrupting collagen fibrils in animal tissue, the method comprising:

presenting of a HIFU apparatus on a skin surface of a patient;

coupling said HIFU apparatus to said skin surface to maximize energy coupling from said HIFU apparatus through said skin surface;

activating said HIFU apparatus to deposit an average fluence (EF) value of at least 35 J/cm 2 such that collagen fibrils below the dermis of the patient are at least 30% disrupted.

2 . The method of claim 1 , wherein the average EF value is at least 100 J/cm 2 .

3 . The method of claim 1 , wherein the average EF value is at least 174 J/cm 2 .

4 . The method of claim 1 , wherein the average EF value is at least 265 J/cm 2 .

5 . The method of claim 1 , wherein said animal tissue comprises human adipose tissue.

6 . The method of claim 1 , wherein said animal tissue comprises human subcutaneous tissue.

7 . The method of claim 1 , wherein said fluence is deposited between the dermis and campers fascia of the patient.

8 . The method of claim 1 , wherein the animal tissue is in a human patient (i.e., the method is applied in vivo).

9 . The method of claim 1 , further comprising moving said energy applicator over the skin surface while depositing said fluence.

10 . The method of claim 1 , wherein the collagen fibrils are at least 50% disrupted.

11 . The method of claim 1 , wherein the collagen fibrils are at least 65% disrupted.

12 . The method of claim 1 , wherein the collagen fibrils are at least 75% disrupted.

13 . The method of claim 1 , wherein the collagen fibrils are at least 80% disrupted.

14 . The method of claim 1 , further comprising denaturing one or more collagen fibrils as a result of depositing said fluence.

15 . The method of claim 1 , further comprising destroying one or more adipose cells when said HIFU apparatus is activated.

16 . The method of claim 1 , further comprising massaging the area treated by said deposit of fluence.

17 . The method of claim 16 , further comprising regularly messaging said treatment area until a wound healing process for the disrupted fibrils is substantially complete.

18 . A method of non-invasively contracting collagen fibrils in animal tissue, the method comprising:

presenting of a HIFU apparatus on a skin surface of a patient;

coupling said HIFU apparatus to said skin surface to maximize energy coupling from said HIFU apparatus through said skin surface;

activating said HIFU apparatus to deposit an average fluence (EF) value of at least 35 J/cm 2 such that collagen fibrils below a dermis of the patient are reduced at least 30% in length.

19 . The method of claim 18 , wherein the average EF value is at least 100 J/cm 2 .

20 . The method of claim 18 , wherein the average EF value is at least 174 J/cm 2 .

21 . The method of claim 18 , wherein the average EF value is at least 265 J/cm 2 .

22 . The method of claim 18 , wherein said animal tissue comprises human adipose tissue.

23 . The method of claim 18 , wherein said animal tissue comprises human subcutaneous tissue.

24 . The method of claim 18 , wherein said animal tissue comprises human tissue between the dermis and campers fascia of the human.

25 . The method of claim 18 , further comprising moving said energy applicator over the skin surface.

26 . The method of claim 18 , wherein the collagen fibrils are reduced at least 40% in length.

27 . The method of claim 18 , wherein the collagen fibrils are reduced at least 50% in length.

28 . The method of claim 18 , further comprising disrupting one or more collagen fibrils when said HIFU apparatus is activated.

29 . The method of claim 18 , further comprising destroying one or more adipose cells when said HIFU apparatus is activated.

30 . A method of measuring skin tone improvement, the method comprising:

locating a region of human tissue beneath a skin surface;

determining an initial condition for said skin surface;

injuring said region of human tissue using a HIFU apparatus such that a volume of disrupted adipose cells and denatured and/or disrupted collagen fibrils are produced;

allowing said injured region of human tissue to resolve; and

determining one or more post operative condition(s) for said skin surface after the injury to said region of human tissue has been created.

31 . The method of claim 30 , wherein determining at least one of said post operative conditions occurs after the injury to the region of tissue has naturally resolved.

32 . A device for non-invasively disrupting collagen fibrils in animal tissue, the device comprising:

a HIFU apparatus designed to be coupled to a skin surface of a patient; and

a computer system configured to activate said HIFU apparatus, when the HIFU apparatus is against the skin of a patient, to:

deposit an average fluence (EF) value of at least 35 J/cm 2 so as to disrupt collagen fibrils; and

focus a focal point of fluence from the HIFU apparatus below the dermis of the patient.

33 . The device of claim 32 , wherein the average EF value is at least 100 J/cm 2 .

34 . The device of claim 32 , wherein the average EF value is at least 174 J/cm 2 .

35 . The device of claim 32 , wherein the average EF value is at least 265 J/cm 2 .

36 . The device of claim 32 , wherein the focal point is directed between the dermis and campers fascia of the patient.

37 . The device of claim 32 , wherein the HIFU apparatus and the computer system are designed such that the HIFU apparatus is movable over the skin surface while depositing said fluence.

38 . The device of claim 32 , wherein the fluence is sufficient such that the collagen fibrils are at least 50% disrupted.

39 . The device of claim 32 , wherein the fluence is sufficient such that the collagen fibrils are at least 65% disrupted.

40 . The device of claim 32 , wherein the fluence is sufficient such that the collagen fibrils are at least 75% disrupted.

41 . The device of claim 32 , wherein the fluence is sufficient such that the collagen fibrils are at least 80% disrupted.

42 . A device for non-invasively contracting collagen fibrils in animal tissue, the device comprising:

a HIFU apparatus designed to be coupled to a skin surface of a patient;

a computer system configured to activate said HIFU apparatus, when the HIFU apparatus is against the skin of a patient, to:

deposit an average fluence (EF) value of at least 35 J/cm 2 so as to reduce collagen fibrils at least 30% in length; and

focus a focal point of fluence from the HIFU apparatus below the dermis of the patient.

43 . The device of claim 42 , wherein the average EF value is at least 100 J/cm 2 .

44 . The device of claim 42 , wherein the average EF value is at least 174 J/cm 2 .

45 . The device of claim 42 , wherein the average EF value is at least 265 J/cm 2 .

46 . The device of claim 42 , wherein the HIFU apparatus and the computer system are designed such that the HIFU apparatus is movable over the skin surface while depositing said fluence.

47 . The device of claim 42 , wherein the fluence is sufficient such that the collagen fibrils are reduced at least 40% in length.

48 . The device of claim 42 , wherein the fluence is sufficient such that the collagen fibrils are reduced at least 50% in length.

49 . The device of claim 42 , wherein the focal point is directed between the dermis and campers fascia of the patient.

Assignments (7)
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: LIPOSONIX, INC.
Reel/Frame 032126/0370 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: SILICON VALLEY BANK
To: LIPOSONIX, INC.
Reel/Frame 032126/0531 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Nov 19, 2013
From: LIPOSONIX, INC.
To: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; CAPITAL ROYALTY PARTNERS II L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031674/0454 →
SECURITY INTEREST - MEZZANINE LOAN Recorded Apr 18, 2013
From: LIPOSONIX, INC.
To: SILICON VALLEY BANK
Reel/Frame 030249/0268 →
SECURITY AGREEMENT Recorded Apr 3, 2013
From: LIPOSONIX, INC.
To: SILICON VALLEY BANK
Reel/Frame 030147/0642 →
CHANGE OF NAME Recorded Jan 25, 2012
From: MEDICIS TECHNOLOGIES CORPORATION
To: LIPOSONIX, INC.
Reel/Frame 027595/0307 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2011
From: DESILETS, CHARLES S.; MARTIN, PATRICK J.; QUISTGAARD, JENS U.; KUNZ, LAWRENCE L.
To: MEDICIS TECHNOLOGIES CORPORATION
Reel/Frame 027109/0738 →